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Abstract
The power of a large clinical trial can be adversely affected by low
recruitment, follow-up and adherence rates. External pilot trials estimate
these rates and use them, via pre-specified decision rules, to determine if
the definitive trial is feasible and should go ahead. There is little method-
ological research underpinning how these decision rules, or the sample size
of the pilot, should be chosen. In this paper we propose a hypothesis test
of the feasibility of a definitive trial, to be applied to the external pilot
data and used to make progression decisions. We quantify feasibility by
the power of the planned trial, as a function of recruitment, follow-up and
adherence rates. We use this measure to define hypotheses to test in the
pilot, propose a test statistic, and show how the error rates of this test
can be calculated for the common scenario of a two-arm parallel group
definitive trial with a single normally distributed primary endpoint. We
use our method to re-design TIGA-CUB, an external pilot trial comparing
a psychotherapy with treatment as usual for children with conduct disor-
ders. We then extend our formulation to include using the pilot data to
estimate the standard deviation of the primary endpoint. and incorporate
this into the progression decision.
1 Introduction
Randomised Controlled Trials (RCTs) often fail to recruit to target [1], lead-
ing to an analysis with less power than intended. Power can also be adversely
affected by large rates of attrition, poor adherence to the allocated treatment
[2], and incorrect specification of a nuisance parameter such as the standard
deviation of a continuous endpoint [3]. A common approach to anticipate these
problems is to run a small version of the intended trial, known as an external
pilot, to obtain estimates of the relevant parameters and decide if, and how, the
definitive trial should be conducted [4, 5]. This decision is typically made with
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reference to so-called Progression Criteria (PCs), a set of conditions which must
be satisfied for the definitive trial to be considered feasible [6]. In the case of
quantitative PCs, parameter estimates are computed using the pilot data and
then compared against threshold values. If all estimates exceed their respective
thresholds, it is recommended that the definitive trial should be conducted. A
recent workshop identified that recruitment, follow-up, and intervention adher-
ence have emerged as common targets of progression criteria [6].
The key role of PCs in pilot trials has led to the CONSORT extension for
randomised pilots requiring their reporting [7], and the NIHR, one of the major
funders of pilot trials in the UK, requiring their pre-specification in the research
plan [8]. There are ethical and economic imperatives to ensuring PCs are appro-
priate. If they are too lenient, we increase the risk of proceeding to the definitive
trial only to discover it is infeasible, fail to answer the scientific question, in the
process wasting resources and subjecting patients to research unnecessarily. If
they are too strict, we increase the risk of failing to conduct a definitive trial
which would in fact have been feasible, and as a result withholding a promis-
ing intervention from patients. Despite all this, there is little methodological
research available to help researchers determine optimal PCs [6].
Another important aspect of external pilot trial design is the choice of sample
size. Here, methods have generally focussed on obtaining a sufficiently precise
estimate of the standard deviation of a continuous primary outcome to inform
the sample size calculation of the definitive trial [3, 9, 10, 11, 12, 13]. These
methods, often reduced to simple rules-of-thumb such as requiring 35 partic-
ipants in each arm [3], are nevertheless widely used to choose pilot sample
size when the estimation of the standard deviation is not the only, or primary,
objective. When the goal of the pilot is to provide estimates of recruitment,
follow-up and adherence rates and use these in PCs, imprecise estimates will be
more likely to meet or miss a PC threshold by chance alone [12, 14] and thus
lead to incorrect progression decisions. This issue will be compounded whenever
there are several PCs, with progression to the definitive trial permitted only if
all are satisfied. As the number of PCs grows, so does the probability of missing
at least one threshold through bad luck, even when the precision around each
individual estimate appears adequate - the so-called ‘reverse-multiplicity’ prob-
lem seen in multiple testing procedures [15, 16]. Although the sample size of
pilots is often justified by reporting the anticipated precision in the estimates of
feasibility parameters (e.g. the widths of confidence intervals), there is no clear
guidance on how precise they should be, or how to weigh precision against the
cost of sampling.
A more formal approach to the design and analysis of external pilot trials
could employ a hypothesis testing framework. Taking this view, progression to
the definitive trial would be determined by comparing an appropriate statistic
to a critical value rather than using several independent PCs. To implement
this approach we must be able to identify levels of recruitment, follow-up and
adherence which would correspond to feasible or infeasible definitive trials, and
identify an approproiate statistic that can differentiate between them. Given
these, the critical value and the pilot sample size can then be chosen with
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regards to the long-run error rates they lead to. Although many authors have
advised against conducting formal hypothesis tests in pilot trials [17, 18, 19, 12],
these warnings have been in the context of tests of effectiveness. Assuming
the effect size of interest is the same in the pilot and the definitive trial and
that conventional type I error rates are used, such a test will have low power.
Tests assessing rates of recruitment, follow-up and adherence will not necessarily
suffer from the same restriction. Moreover, it should be emphasised that the
conventional method of pre-specifying several PCs and using these to map pilot
data to progression decisions is mathematically equivalent to a multivariate
hypothesis test, but without hypotheses being defined and therefore without
any understanding of the statistical properties of the resulting procedure. A
formal approach is therefore of interest, both to gain an understanding of current
practice and to investigate if, and how, progression decisions can be improved.
The remainder of the paper is structured as follows. First, we will define
the specific problem under consideration in Section 2. In Section 3 we will
describe a formal hypothesis test of feasibility based on recruitment, follow-up
and adherence rates. We will show how null and alternative hypotheses can
be defined in terms of the power which will be obtained in the definitive trial,
define an appropriate test statistic, and use the statistic’s sampling distribution
to define and calculate type I and II error rates. We then use the method to
re-design an external pilot trial comparing a psychotherapy with treatment as
usual for children with conduct disorders in Section 4. In Section 5 we study
the properties of the proposed test in a range of scenarios and compare its
performance against the conventional approach to choosing pilot sample size
and PCs. We extend the method in Section 6 to allow for the additional goal
of estimating the standard deviation of the primary outcome, before concluding
with a discussion of implications and limitations in Section 7.
2 Problem and notation
Consider an external pilot planned in advance of a large two-arm parallel group
trial which will compare an intervention with control based on a normally dis-
tributed primary endpoint. We assume that the definitive trial has a target
sample size nt to be recruited from a pool of ne eligible patients. Each of the
ne eligible patients will agree to take part in the trial with probability φr, and
recruitment will continue until either the target nt has been reached or the pool
of eligible patients has been exhausted. We denote by N the total number of
participants in the definitive trial, a random variable with a truncated binomial
distribution of size ne, probability φr, and constrained to be less than or equal
to nt.
We assume that the N recruited participants of the definitive trial will be
randomised equally between the two arms. In the control arm, F0 partici-
pants will be successfully followed up with probability φf . Thus, F0 | N ∼
Bin(N/2, φf). In the intervention arm, participants may or may not be followed-
up, and may or may not adhere to the intervention. We allow for the possibility
3
that these binary outcomes will be correlated at the participant level by us-
ing a multinomial distribution, such that participants will both adhere and be
followed up with probability p11; adhere, but be lost to follow up with proba-
bility p10; not adhere, but be successfully followed up with probability p01; and
neither adhere nor be followed up with probability p00. We can parametrise
the model with marginal rate of follow-up φf , rate of adherence conditional on
being followed-up, φa, and an odds ratio φor:
p11 = φaφf
p01 = φf − p11
p00 =
φor p01(1− p11 − p01)
p11 + φor p01
p10 = 1− p11 − p01 − p00.
Note that we have assumed a constant marginal rate of follow-up in the inter-
vention and control arms. We denote the number followed-up in the intervention
arm by F1, where F1 | N ∼ Bin(N/2, φf), and the number of those followed-up
who also adhere by A, where A | F1 ∼ Bin(F1, φa).
We assume that non-adherence will be absolute in the sense that no treat-
ment effect will be gained. We model the outcome for patient i in arm j as
yi,j = tjai,jµ+ ei,j ,
where ti and ai,j are binary indicators of treatment arm and adherence re-
spectively, µ is the difference in mean outcome between the two groups, ei,j ∼
N(0, σ2) is the residual term, and we have omitted the usual constant intercept
for notational simplicity and without loss of generality. We will assume initially
that σ2 is known, although this will be relaxed in Section 6. For simplicity
the primary analysis of the definitive trial is assumed to be a complete-case
intention-to-treat z-test of the observed mean difference Y¯1 − Y¯0 with a null
hypothesis of H0 : µ = 0, where Y¯j =
1
Fj
∑Fj
i=1 yi,j .
We assume that the external pilot trial will take the same form as the defini-
tive trial, but on a smaller scale. The model of recruitment, follow-up and
adherence in the pilot trial is assumed to be the same as for the definitive trial
apart from one aspect: for the small external pilot trial we will continue re-
cruiting until the target pilot sample size of np has been reached. Thus, we
consider the achieved sample size of the pilot to be known and fixed, with the
number of eligible patients approached but declining to participate following a
negative binomial distribution S ∼ NB(np, φr). Denoting the parameters by
φ = (φr, φf , φa), the external pilot trial will provide an estimate φˆ. Our goal is
to show how a decision rule mapping φˆ to the set {stop, go} of progression de-
cisions can be defined, and how the parameters of the rule and the pilot sample
size np can be chosen.
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3 A hypothesis test of feasibility
A decision rule mapping pilot estimates φˆ to the set {stop, go} of progression
decisions can be specified and evaluated under a framework of hypothesis testing.
Specifically, given a model of the pilot trial and thus of the sampling distribution
for φˆ, we can calculate the probabilities of a given decision rule leading to ‘stop’
and ‘go’ decisions conditional on the true parameter values φ. If we can identify
those values φ for which we would like to make a ‘stop’ decisions, and likewise
those for which we would like to make a ‘go’ decision, we can calculate long-run
error rates of the first and second kind and use these to inform our choice of
decision rule and of pilot trial sample size.
In this section we first propose that a planned definitive trial can be classified
as either feasible or infeasible according to the power it will have in its final
analysis. Power will be determined by the parameter φ, and so this provides a
means to define null and alternative hypotheses to be tested in the pilot trial.
We begin by deriving an expression for the definitive trial power as a function of
φ, and then go on to define hypotheses. We then propose a test statistic to be
used in the pilot trial and provide its sampling distribution, allowing long-run
error rates to be calculated. Finally, we show how these error rates can be used
to determine an optimal design for the pilot trial, encompassing both its sample
size and the decision rule to be used at its conclusion.
3.1 Power of the definitive trial
The power of the definitive trial is determined by the sampling distribution of
the difference in group means, Y¯1 − Y¯0. We assume that the definitive trial
per-arm sample size will be greater than 30, allowing the sampling distributions
of the group means to be approximated by normal distributions. The power of
the definitive trial to detect a difference µ is then
Φ
(
E[Y¯1 − Y¯0 | µ]√
V ar(Y¯1 − Y¯0 | µ)
− z1−α
)
,
where α denotes the (one-sided) type I error rate and Φ denotes the standard
normal distribution function. The expectation and variance of the mean differ-
ence will depend on the values of µ, φ, nt and ne. For clarity, we will drop the
terms µ, nt and ne from our notation as they can be considered fixed, and focus
on power as a function of φ, denoted g(φ). Then,
g(φ) = Φ (x(φ) − z1−α) .
The appendix will show that
x(φ) =
φaµ
√
φfE[N | φr]√
4σ2 + 2µ2φa(1− φa)
,
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where E[N | φr] is the expected number of participants recruited into the defini-
tive trial when the recruitment rate is φr,
E[N | φr] =
nt−1∑
k=0
k
(
ne
k
)
φkr (1− φr)
ne−k + ntPr(C ≥ nt),
and C ∼ Bin(ne, φr).
3.2 Hypotheses and test statistic
We propose to define null and alternative hypotheses by considering the power
which would be obtained in the definitive trial which will aim to recruit nt
participants from a pool of ne eligible patients. We require a power threshold
p0 to be identified, such that if the power of the definitive trial was known to be
less than or equal to p0 then it would be considered infeasible and we would like
to minimise the chance of mistakenly proceeding to it (a type I error). Similarly,
we require a second threshold p1 such that if the definitive trial had a power of
at least p1 we would considered it to be feasible and would like to minimise the
chance of mistakenly concluding otherwise (a type II error).
Given the thresholds p0, p1, we can define the null (alternative) hypothesis
as those parameter values which would lead to a definitive trial with power less
than or equal to p0 (greater than or equal to p1). We denote these hypotheses
by Φ0,Φ1 respectively. We can express these in terms of the previously defined
x(φ):
Φ0 = {φ ∈ Φ | x(φ) ≤ x0}
Φ1 = {φ ∈ Φ | x(φ) ≥ x1},
where
xi = Φ
−1(pi) + z1−α.
Testing feasibility in the external pilot trial will involve calculating a statistic
based on the pilot estimate φˆ and proceeding to the definitive trial if and only
if it exceeds some pre-specified critical value c. A natural choice of statistic is
x(φˆ). We can then define the type I and II error rates of the pilot trial, which
will be determined by the pilot sample size np and the critical value c:
α(np, c) = max
φ∈Φ0
Pr[x(φˆ) > c | φ, np],
β(np, c) = max
φ∈Φ1
Pr[x(φˆ) < c | φ, np].
3.3 Power of the external pilot trial
To obtain type I and II error rates for a particular pilot trial of sample size np
per arm and critical value c, we require an expression for the probability that
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the pilot test statistic will be greater than c conditional on some true parameter
value φ, denoted
h(np, c, φ) ≡ Pr[x(φˆ) > c | np, φ].
Denote by naf the value taken of the multinomial variable recording follow-
up and adherence outcomes, and by Naf the set of possible realisations. The
power of the pilot trial can be calculated by considering each value in Naf and
calculating the probability that the observed recruitment rate will be sufficient
for the test x(φˆ) > c to pass. Given adherence and follow-up estimates φˆa, φˆf ,
this condition will be met when the estimated recruitment rate φˆr is such that
E[N | φˆr] >
c2(4 + 2µ2φˆa(1− φˆa)
µ2φˆ2aφˆf
= n˜.
Since φˆr = 2np/(2np+s), we can find the largest value of s such that E[N | φˆr] >
n˜. Noting this will be a function of naf and denoting it by s˜(naf ), the power of
the pilot trial is then
h(np, c, φ) =
∑
naf∈Naf
Pr [S ≤ s˜(naf ) | φ] paf(naf | φ). (1)
Here, paf (.) is the multinomial density describing follow-up and adherence out-
comes.
Equation 1 allows for follow-up and adherence outcomes to be correlated,
which may be appropriate if we expect that a participant who does not adhere
to the intervention delivery is also less likely to adhere to other aspects of the
trial protocol, including data collection. If this is not thought to be the case, we
can assume follow-up and adherence are independent and equation 1 simplifies
to
h(np, c, φ) =
np∑
a=0

2np∑
f=0
Pr [S ≤ s˜(a, f) | φ] pf (f | φ)

 pa(a | φ),
where pf (.) and pa(.) are the densities describing the follow-up and adherence
outcomes respectively. By avoiding a summation over the multinomial space
Naf , which can be very large for moderate np, this reduces the number of terms
to be evaluated and thus decreases computation time.
3.4 Operating characteristics
Recall that the type I (II) error rate of the pilot trial is defined as the largest
probability of proceeding (failing to proceed) to the definitive trial when the
true parameter is in the null (alternative) hypothesis. That is,
α(np, c) = max
φ∈Φ0
h(np, c, φ),
β(np, c) = max
φ∈Φ1
1− h(np, c, φ).
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Designing a pilot trial could proceed by considering a set of candidate sample
size values np and critical values, solving the above optimisation problems for
each, and then choosing the (np, c) pair which is deemed to give the best bal-
ance between the costs of sampling and the two types of errors. This approach
has the drawbacks of requiring an appropriate range of c a priori, and a lack of
sharing information between the discrete optimisation problems. An alternative
formulation which avoids these drawbacks is to (for fixed np) cast the problem
as one of constrained bi-objective optimisation over the space R × Φ × Φ, si-
multaneously searching for a critical value c and two points in the parameters
space, φ0 and φ1, which maximise type I and II error rates whilst satisfying the
constraints that φ0 ∈ Φ0 and φ1 ∈ Φ1. Formally, we solve
max (h(np, c, φ0), 1− h(np, c, φ1)) (2)
subject to c ∈ R,
φ0 ∈ Φ0,
φ1 ∈ Φ1.
A problem of this nature can be solved numerically using the NSGA-II algo-
rithm [20], as implemented in the R package ‘mco’ [21]. It will provide a set of
critical values and corresponding points in the null and alternative hypotheses
offering different balances between type I and type II error rates. These error
rates can then be plotted for a number of choices of np, and an appropriate
design selected from them. To ensure a reasonably fast computation time, we
implemented the function h(np, c, φ) in C++ via the ‘Rcpp’ package[22]. Full
details, including all code used to produce the results described throughout the
paper, are provided in the supplementary materials.
3.5 Comparison
An alternative to the proposed test is to follow the conventional approach and
make the stop/go decision based on several independent progression criteria.
Decision rules are then defined by three critical values c = (cf , ca, cr), where
we proceed to the definitive trial only when φˆf > cf , φˆa > ca and φˆr > cr.
Assuming independence between the parameter estimates, the probability of
this event is
f(np, c, φ) = Pr[φˆr > cr | φ]× Pr[φˆf > cf | φ]× Pr[φˆa > ca | φ]
= Fs(2np/cr − 2np | φ)× [1− Ff (2npcf | φ)]× [1− Fa(npca | φ)],
where Fs(.), Ff (.) and Fa(.) are the cumulative distribution functions for the
random variables S, F and A in the pilot, respectively. For any given choice of
pilot sample size np and progression criteria c, type I (II) error rates are defined
as before by maximising f(np, c, φ) over the null (alternative) hypotheses. To
find a set of progression criteria which offer different trade-offs between minimis-
ing type I and II error rates, we solve the following bi-objective optimisation
problem:
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min
c∈[0,1]3
(
max
φ∈Φ0
f(np, c, φ), min
φ∈Φ1
1− f(np, c, φ)
)
.
We use NSGA-II again to solve the outer bi-objective minimisation prob-
lem. For the inner optimisation problems, we assume that the solutions will lie
on the boundaries of the hypotheses and therefore have a constraint, φ ∈ Φi,
meaning that the search is over two dimensions. For example, we can search
over (φr, φa) ∈ [0, 1]
2 since φf will then be determined by
φf =
4σ2 + 2µ2φa(1− φa)x2i
(φaµ)2E[N | φr]
.
Given the low dimension of the search space, we obtain approximate solutions
by searching over a fine grid of values for (φr , φa), in increments of 0.005. This
procedure is computationally efficient since the error rates at each point in the
grid can be calculated in a vectorised manner, with very little overheads in
comparison to a sequential evaluation. Again, full details are provided in the
supplementary materials.
4 Application to an external pilot trial of a psy-
chotherapy intervention
TIGA-CUB [23] was a two-arm, parallel group, individually-randomised exter-
nal pilot trial aiming to determine the feasibility of a definitive trial comparing
second-line, short-term, manualised psychoanalytic child psychotherapy with
treatment as usual for children with conduct disorders. The trial’s objectives
included estimation of the rate at which eligible dyads (where a child - carer
dyad was the unit of randomisation and observation) consented to take part in
the trial; the level of missing data in the primary outcome; the rate of adherence
to the intervention; and the parameters required for the sample size calculation
of the main study. Progression criteria relating to recruitment, follow-up and
adherence rate were specified, with the definitive trial to go ahead only if:
1. Recruitment was to target;
2. Attendance was at more than 50% of sessions in the intervention arm;
3. At least 75% of follow-up data was collected.
The sample size was determined by using the rule-of-thumb that 30 par-
ticipants per arm is sufficient to estimate a standard deviation of a continuous
primary outcome which is common across arms [17]. Assuming 90% of pilot par-
ticipants are followed-up, a sample size of 60 participants in total was chosen
and justified in terms of the expected width of 95% confidence intervals around
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estimates of the standard deviation (0.39 multiplied by SD), the follow-up rate
(±7%), and the adherence rate (between ±8% to 18%).
To revisit the choice of sample size and progression criteria, we first need
to define some aspects of the planned definitive trial. We begin by setting the
minimal clinically important effect size to be detected and the outcome standard
deviation, here assumed to be µ = 0.3 and σ2 = 1 respectively. We then decide
on the planned design of the definitive trial, in terms of the number of eligible
patients who will be approached and the target total sample size. For illustrative
purposes we suppose these are equal to ne = 1000 and nt = 514. Note that this
target sample size, after allowing for 10% attrition, would lead to a definitive
trial with 90% power to detect µ = 0.3 when using a two-sided type I error rate
of 0.05.
We decide that if the planned definitive trial were to have at least 80%
power, after accounting for any issues with recruitment, follow-up or adherence,
we would like to obtain a ‘go’ decision from the pilot trial. In terms of our
notation, we set p1 = 0.8. Similarly, we consider that if the trial could only
provide a power of 65% or less then we would like to obtain a ‘stop’ decision
from the pilot, and so we set p0 = 0.65. These parameters specify the null and
alternative hypotheses which are to be tested in the pilot trial. They can be
visualised by considering pairs of recruitment and adherence rates and finding
the corresponding value of follow-up rate that would lead to a definitive trial
power of exactly p0 = 0.65 for the null, or p1 = 0.8 for the alternative. The
resulting surfaces, which represent the boundaries of the hypotheses, can then
be plotted as in Figure 1. In this case, we see that the two hypotheses have
a similar shape, but with the alternative shifted towards higher (and therefore
better) values of follow-up, recruitment and adherence rates. The trade-offs
between the three parameters are clear, with decreases in one being compensated
by increases in the others in order to maintain power at either p0 or p1. As the
recruitment rate increases beyond around 50% there are no opportunities for
trade-offs with the remaining parameters because it becomes certain that the
recruitment target of nt will be met, and so the sample size will not increase
any further.
4.1 Fixing p0 and p1
Given the hypotheses, and assuming that follow-up and adherence rates are
independent, we can now consider different sample sizes and progression criteria
and calculate the error rates they lead to. For illustration, we consider pilot trial
sample sizes of np = 30, 50, 70 per arm and solve the optimisation problem 2 for
each case. The resulting operating characteristics are plotted in Figure 2 (solid
lines). In this case we see that error rates with the original sample size of np = 30
are quite poor, in comparison to the nominal values typically seen in early phase
drug trials. For example, a type I error rate of 0.09 corresponds to a type II
error rate of 0.44. As we would expect, increasing the external pilot sample size
leads to improved error rates. A pilot sample size of 50 participants per arm, for
example, reduces the type II error rate to around 0.23 whilst maintaining type
10
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Figure 1: Values of recruitment, follow-up and adherence parameters for leading
to a definitive trial power of p0 = 0.65 (i.e. the boundary of the null hypothesis,
left panel), or p1 = 0.8 (i.e. the boundary of the alternative hypothesis, right
panel).
I error rate at 0.09. We might conclude from these results that TIGA-CUB’s
original sample size of 30 per arm was too small to make reliable progression
decisions, and that increasing to somewhere between 50 and 70 per arm could
have been worthwhile.
Given the possible choices of error rates and sample size given in Figure
2 we can select that which best reflects our priorities. For example, suppose
we select the point with np = 50, α = 0.09 and β = 0.23. The corresponding
critical value is c = 2.6422, so the pilot trial will produce a ‘go’ decision if
x(φˆ) > 2.6422 and a ‘stop’ decision otherwise. It may be helpful to transform
the decision rule to the power scale, allowing us to specify the decision rule as:
‘go’ if the predicted power of the main trial, based on the pilot estimate φˆ, is
greater than Φ(2.6422− z1−0.025) = 0.7524; otherwise, ‘stop’.
For comparison, we also evaluated the error rates resulting from the conven-
tional approach to defining PCs described in Section 3.5. For each of the pilot
sample sizes np = 30, 50, 70 we searched over the full set of possible PC thresh-
olds c to identify a non-dominated subset, where a threshold c is non-dominated
if there does not exist another threshold c′ which leads to lower type I and lower
type II error rates. In this example we find that setting several independent PCs
will lead to very poor error rates. For example, when np = 30 we must accept a
type II error rate of 0.9 (i.e. a power of 0.1) to obtain a type I error rate of 0.1.
In fact, regardless of the specific thresholds used, error rates will be no better
than what would be obtained when making progression decisions by tossing a
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Figure 2: Type I (α) and type II (β) error rates obtained for a range of critical
values c and pilot sample sizes np when using the proposed method (solid lines).
Error rates available when using conventional progression criteria are shown for
comparison (dashed lines).
(possibly biased) coin. Increasing the pilot sample size does not improve error
rates, but actually makes them worse. These counter-intuitive results can be
explained by the fact that independent PCs are of an intrinsically conjunctive
nature, requiring all three endpoints to show a positive result. In contrast, our
hypotheses have been defined in a more disjunctive manner, where a positive
result in only one endpoint may be enough to indicate overall feasibility due to
the acknowledged trade-offs involved. To illustrate the point further, consider
the case of a pilot trial sample size tending to infinity so that φˆ = φ and pilot
error rates will be either 0 or 1. In this idealised scenario, a type II error rate
of β = 0 will be obtained only if cf < φf , ca < φa, cr < φr ∀ φ ∈ Φ1. For this
infinite sample size to also lead to α = 0, a necessary condition is therefore that
φ′ =
(
min
Φ1
φf , min
Φ1
φa, min
Φ1
φr
)
6∈ Φ0.
For example, in this case we find φ′ = (φ′f = 0.679, φ
′
a = 0.83, φ
′
r = 0.35), but
x(φ′) = 1.91 < x0 and so φ
′ is in the null hypothesis. Thus, a pilot sample size
tending to infinity and with independent PC thresholds chosen to give β = 0
will have α = 1.
Aside from the overall inefficiency of independent PCs, we found that there
are many possible choices for independent PC thresholds which are dominated
by others. For example, for np = 30 we find that c = (cf = 0.705, ca =
0.865, cr = 0.373) leads to type I and II error rates of 0.53 and 0.72 respectively,
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whereas c′ = (cf = 0.6, ca = 0.8, cr = 0.4) will give a worse type I error (0.74)
and a worse type II error (0.88). This suggests that if independent PCs are
to be used under the conventional approach, as they were in TIGA-CUB, the
choice of threshold values should be informed by a careful statistical analysis of
their properties if we are to avoid needlessly inefficient decision rules.
4.2 Fixing p1 and β
An alternative approach to pilot trial design results from the observation that,
if the alternative hypothesis threshold p1 is fixed, we can find a critical value
c which will lead to some desired pilot type II error rate independently of p0.
Keeping c fixed at this value, we can then look at a range of values for p0 and
plot the corresponding type I error rate. The evaluation of a pilot with sample
size np and critical value c can then be based on the probability of making a go
decision as a function of p0, rather than focussing on a specific point.
For example, suppose we take p1 = 0.8 as before and ask for a type II error
rate of 0.1. We find that, for a pilot sample size of 30 per arm, a critical value of
c = 2.46 will achieve this error rate. We can then keep c fixed at this value and
calculate the corresponding type I error rate as we vary p0. Doing this again
for pilot sample sizes of 50 and 70, we plot the results in Figure 3. We see that
while a large pilot sample of np = 70 will ensure there is only a 0.03 probability
of proceeding to a definitive trial with a true power of p0 = 0.6, it will also mean
that when p0 ≈ 0.725 there will only be a 0.5 chance of proceeding. This might
be considered rather low, when we have defined the alternative hypothesis using
p1 = 0.8. In comparison, the associated values when np = 30 are 0.24 and 0.78.
5 Evaluation
To understand to what extent the results given in the above illustrative ex-
ample will be found more widely, we applied both the proposed test and the
conventional method to a number of different scenarios. Recall that a scenario
is defined by: the parameters describing the primary outcome of the definitive
trial (mean µ and variance σ2); its planned design (target sample size nt and
number of eligible patients ne); and the power thresholds used to define our null
and alternative hypotheses (p0 and p1 respectively). Scenarios are distinguished
from one another in terms of the null and alternative hypotheses they imply,
which are determined by x(φ) and the thresholds p0, p1.
We will fix p1 = 0.8 throughout, and will consider p0 = 0.6, 0.65, 0.7. We note
that the denominator in x(φ) will be dominated by its first term for the typical
standardised effect sizes (i.e less than around 0.5). The expected definitive trial
sample size in the numerator depends on ne, nt and φr and so, for fixed φ, the
terms µ, σ2, ne and nt reduce to one factor when determining x(φ). As such,
we focus on varying one of these parameters while keeping the others fixed.
We choose to fix µ = 0.3, σ2 = 1, ne = 1000 whilst varying nt. We consider
nt = 468, 514, 562, corresponding to the target sample size which would be
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Figure 3: Type I error rates for pilot trials of different sample sizes np, as a func-
tion of the null hypothesis parameter p0 and keeping type II error maintained
at 0.1.
obtained when asking for 90% power and allowing for attrition of 0, 10 and 20%
respectively. For each scenario we calculated the operating characteristics of
an external pilot with sample size np = 30, 50, 70 per arm. The resulting error
rates are illustrated in Figure 4.
We see that inflating the target sample size leads to a small increase in pilot
error rates. For example, for np = 30, nt = 468 and p0 = 0.7 (top right panel),
the pilot can have error rates of α = 0.08 and β = 0.58. Increasing the target
sample size to nt = 562 gives an increased type II error rate of β = 0.77 whilst
maintaining type I error. This general behaviour can be explained by noting
that recruiting more participants will mean we can tolerate worse follow-up
and/or adherence whilst maintaining power. As a result the hypotheses will be
larger, and in general we can expect error rates to increase as the size of the
hypotheses they are defined over increase. Error rates are also sensitive to the
power used to define the null hypothesis. For example, with pilot sample size
np = 30 and definitive trial target sample size nt = 468 but reducing p0 from
0.7 to 0.6, one can reduce the type II error rate from 0.58 to 0.20 at the cost of
a small increase in the type I error rate from 0.08 to 0.11. In all scenarios we
see a considerable improvement in error rates when we increase the pilot sample
size from 30 to 50 per arm, with less of a subsequent improvement moving from
50 to 70. Although the choice of sample size for a given pilot trial will depend
on the costs of sampling the consequences of type I and II errors, our results
suggest that a sample size of around 50 per arm should be sufficient whenever
p1 = 0.8 and p0 ≤ 0.65.
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Figure 4: Type I (α) and type II (β) error rates obtained for a range of critical
values c and pilot sample sizes np when using the proposed method (solid lines)
and the conventional approach (dashed line). The power used to define the null
hypothesis increases from left to right, p0 = 0.6, 0, 65, 0.7, while the target sam-
ple size of the definitive trial is increased from top to bottom, nt = 468, 514, 562.
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With regards to the conventional approach of setting several independent
PCs, we see similar trends in terms of the effects of changing nt and p0. As
with the proposed method, error rates tend to increase as nt increases, but in
this case at a higher rate. Reducing p0 leads to improved error rates. Even in
the best scenario we considered, with nt = 468 and p0 = 0.6, the error rates
which can be obtained using independent PCs are still no better than those of a
random coin toss. We can conclude from these results that, when the proposed
method of defining hypotheses is deemed appropriate, independent PCs should
not be used to guide progression decisions in external pilot trials.
6 Extension - unknown variance
We have considered how recruitment, follow-up and adherence rates all affect
the power of the definitive trial, and have shown how these can be assessed in
an external pilot trial as part of a hypothesis test. Another parameter which
affects the power of the definitive trial is the standard deviation of the outcome
measure: recall from Section 3.1 that the conditional power is
g(φ, σ) = Φ (x(φ, σ) − z1−α) ,
where
x(φ, σ) =
φaµ
√
φfE[N | φr ]√
4σ2 + 2µ2φa(1− φa)
,
The methods described so far have assumed σ is known. When this is not
the case we can extend our approach by including the true value of σ in the
definition of the hypotheses Φ0 and Φ1, and the pilot estimate σˆ in the test
statistic x(φˆ, σˆ). This will allow for high variability in the outcome measure,
which may lead to a trial with infeasibly low power, to be identified at the pilot
stage.
For notational simplicity and ease of computation we will focus on the case
where follow-up and adherence are independent, but the method extends natu-
rally to the more general case. The power of the pilot trial is now approximately
h(np, c, φ, σ) =
np∑
a=0

2np∑
f=0
(
smax∑
s=0
[∫ y
0
pσˆ2(σˆ
2|s, a, f, φ) dσˆ2
]
ps(s|φ)
)
pf (f |φ)

 pa(a|φ),
where pσ2(.) is the density function of the sample variance, specifically,
σˆ2 | f ∼
σ2χ2f−1
f − 1
.
The approximation comes from the fact that we would like to sum over the
full range of possible values for s ∈ [0,∞) but must limit the summation to
some value smax. We set smax to the upper 0.999 quartile of the negative
binomial distribution with parameter φr, ensuring an accurate approximation
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whilst avoiding excessive computation. The upper limit of the integral, y, is
the largest value that the sample variance could take and still lead to the test
x(φˆ, σˆ2) > c passing, given s, a and f . It is:
y =
φˆ2aµ
2φˆfE[N | φˆr ]
4c2
−
1
2
µ2φˆa(1 − φˆa).
Empirically, we find that both type I and II error rates increase as the
standard deviation decreases. To avoid the trivial situation where error rates
tend to 1 as σ tends to zero, we include a lower limit on σ∗ in the definitions of
the hypotheses Φ0 and Φ1. These are now defined as
Φ0 = {φ ∈ Φ, σ > σ∗ | g(φ, σ) <= p0},
Φ1 = {φ ∈ Φ, σ > σ∗ | g(φ, σ) >= p1}.
To illustrate the effect of allowing for uncertainty in σ, we calculated the
error rates available when np = 50, nt = 514, p0 = 0.65 and p1 = 0.8, and the
lower limit was taken to be σ∗ = 0.8. We then compared these error rates with
those previously obtained when it was assumed that σ = 1. For example,when
σ was assumed known a pilot trial type I error rate of 0.12 allowed a type
II error rate of 0.23. Maintaining the same type I error but now estimating
σ in the pilot increases type II error to 0.39. The detriment stems from two
issues. Firstly, by using the pilot variance estimate in the test statistic x(φˆ, σˆ)
its sampling variability increases. Secondly, by allowing for the lower limit
of σ∗ = 0.8 we accommodate lower values of the rates φr , φa and φf in our
hypotheses, enlarging them and thus allowing more extreme error rates to be
located. Error rates can be improved to some extent through increasing sample
size. For example, increasing np from 50 to 70 will lead to a type II error rate
of 0.34 whilst maintaining the type I error rate at 0.12.
7 Discussion
We have proposed a statistical test which simultaneously assesses recruitment,
follow-up and adherences rates in order to anticipate and mitigate related prob-
lems which would render the planned definitive trial infeasible. We have shown
that, without increasing the sample size of the pilot trial beyond typical values,
the test can limit the probability of mistakenly running an underpowered trial
whilst reliably ensuring well-powered trials will progress. We have described
how the test can be extended to include the common pilot objective of estimat-
ing an unknown standard deviation nuisance parameter, and found that for this
to be incorporated the sample size of the pilot trial will have to be increased if
operating characteristics are to be maintained.
The proposed method leads to reasonable error rates when the pilot sam-
ple size is around 50 patients per arm. While this is more than some common
rules-of-thumb for choosing an external pilot sample size such as 25 [13] or 35
[3] per arm, it remains reasonable in the context of a pilot preceding a much
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larger trial. In comparison, our study of the conventional approach to setting
progression criteria has shown that, at least in the scenarios we considered, no
amount of increase to the pilot sample size will lead to reasonable error rates.
Although the proposed method is more complicated than the conventional ap-
proach, it is flexible in the sense that it can be applied in its full generality
when the aim of the pilot is to estimate recruitment, adherence, follow-up and
the outcome standard deviation, but could equally be used in the special case
where only a subset of these parameters are of interest. We have produced a
robust and efficient implementation in R and have provided this in the supple-
mentary material, where we also show how to reproduce the results given in this
paper.
Some assumptions have been made for simplicity and ease of explanation.
In particular, we assumed that the rate of follow-up will be constant across the
intervention and control arms of the trials. Relaxing this assumption is possible,
although it would add another dimension when searching for the maximum error
rates of a given pilot sample size and critical value. We also assumed that adher-
ence is absolute, with non-adherers receiving no treatment effect. Violation of
this assumption will lead to a general under-estimation of definitive trial power,
which will affect the construction of the pilot hypotheses and subsequently the
pilot error rates. Finally, we note assumptions of a complete-case ITT analysis
(as we have done for the definitive trial) and of the successful recruitment of the
target sample size (as we have done for the pilot trial) are both standard when
carrying out power calculations.
We have focussed on a specific problem where the definitive trial will have a
randomised two-arm design with a single, normally distributed primary outcome
measure. Our method could be applied directly to any problem with an outcome
that can be approximately modelled as normal. For example, a binary endpoint
can be incorporated using a normal approximation if the definitive trial sample
size is sufficiently large; or a cluster randomised trial could be addressed if the
endpoints are all measured at the cluster level and the variance parameters of
the primary outcome were known. To extend the method to other problems we
would require an expression for the power of the definitive trial (as a function
of parameters φ), a statistic to use in the pilot trial, and an expression for
the power of the pilot trial using that statistic. When analytic forms of the
power functions cannot be found, they can be approximated using simulation
[24] and, in principle, the optimisation problem in Section 3.4 could be solved
as before. In practice, evaluating two objectives and two constraints using
simulation would be computationally demanding and the NSGA-II algorithm
would take an infeasibly long time to converge. Future work could explore
how efficient global optimisation algorithms [25] could be used to solve these
problems in a timely manner. A further extension could consider internal pilot
trials, where the pilot data is combined with the definitive data in the final
analysis. This would, however, induce a correlation between the pilot trial
progression decision and the final test of treatment effectiveness. As a result,
appropriate adjustments would be needed to ensure the type I error rate of the
final analysis can be controlled at the nominal level.
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Our method requires the specification of the number of eligible patients ne
and the target sample size nt for the definitive trial. In practice, the exact
value of these parameters may not be known at the pilot design stage, and in
particular the results of the pilot may influence how they are set. However,
note that ne and nt are only used, in conjunction with the power thresholds
p0, p1, to specify the null and alternative hypotheses Φ0,Φ1. Thus, we are free
to use some hypothetical choices of ne and nt providing we accept that any
point φ ∈ Φi, i = 0, 1 will remain as such even if ne or nt are changed. For
example, we may have defined the null hypothesis so that φ ∈ Φ0 if and only
if a definitive trial with design nt, ne would have less than 60% power under φ.
For that same φ, we could increase the definitive trial sample size to some n′e, n
′
t
such that its power would increase to 90%. Under our formulation we would
still consider φ to be in the null, and would want to avoid running a definitive
trial with sample size n′e, n
′
t and power g(φ, n
′
e, n
′
t) = 0.9. This corresponds to
a judgement that the improvement in power obtained by moving from ne, nt to
n′e, n
′
t is not sufficient to justify the increased cost of sampling.
Our method leads to a binary stop/go decision. Increasingly, progression
criteria in pilot trials are incorporating three outcomes, adding an additional
intermediate ‘amber’ decision between the ‘red’ stop and ‘green’ go [6]. The
intention is that if the pilot estimate is neither clearly good nor bad, but some-
where between, then it may be possible to make some modifications to the
intervention or the trial protocol which would ensure the definitive trial will be
feasible. A possible extension to the testing framework outlined could consider
defining three hypotheses where the decisions ‘stop’, ‘modify’ or ‘go’ would be
optimal. In practice, the pilot trial could be designed using the proposed method
and assuming no modifications will be possible, and, in the event that we wish
to make modifications, another pilot could be done to assess the effect of these.
This would appear to be in line with the iterative process of complex intervention
development and evaluation suggested in the MRC framework[4]. Alternatively,
if the modifications are made and we proceed directly to the definitive trial, we
should be clear that the error rates associated with the pilot trial as designed
will no longer apply.
In addition to the recruitment, follow-up and adherence rates and the stan-
dard deviation we have considered in this paper, another parameter which would
be of interest when deciding to run a definitive trial is the treatment effect µ
[26]. In particular, if the true treatment effect is very small, we would ideally
like to recognise this at the pilot stage and declare futility. To incorporate such
an assessment into our method we could consider a bivariate test in the pilot,
simultaneously assessing the power of the definitive trial and the true treat-
ment effect. Defining the null and alternative hypotheses for such a test may be
challenging, as it would require specifying the trade-offs we would be willing to
make between definitive trial power and treatment effect. Future research could
consider how methods for testing two outcomes in phase II drug trials[27, 28]
could be applied in this context.
The proposed method could benefit from further methodological research.
For example, the pilot test statistic was defined in a pragmatic manner and is
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not guaranteed to be optimal, and so further research could consider alternative
statistics which might be more powerful when testing the hypotheses we have
defined. A further criticism of the proposed method is the simplicity of the
decision rule it suggests. Particularly in the case of external pilot trials of
complex interventions, we would expect the decision of if and how the definitive
trial should be conducted to be informed by many factors beyond the pilot
estimates of a handful of parameters, not least qualitative outcomes. However,
we believe the method will still provide a useful guide to decision making, and
allows for the choice of pilot sample size to be considered more fully. This view
is supported by the continued prevalence of hypothesis testing in the design and
analysis of all types of clinical trials, where the final decision is rarely made by
rigidly following the result of the test.
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Appendix
Recall that the sample means are
Y¯1 =
A
F1
µ+
1
F1
F1∑
i=1
ei,1,
Y¯0 =
1
F0
F0∑
i=1
ei,0,
where Fj denotes the number of participants in arm j who are followed-up, andA
denotes the number of participants in the intervention arm who both adhere and
are follow-up. These sample means have expectations E[Y¯1|φ] = E[
A
F1
µ|φ] = φaµ
and E[Y¯0|φ] = 0. For the variance of the intervention group mean, we have by
the law of total variance that
V ar(Y¯1) = E[V ar(Y¯1|F1, A)] + E[V ar(E[Y¯1|F1, A]|F1)] + V ar(E[Y¯1|F1]). (3)
Taking each of these terms in turn:
E[V ar(Y¯1|F1, A)] = E
[
σ2
F1
]
=
2σ2
φfE[N ]
,
where E[N ] is the expected number of participants recruited to the trial and
randomised equally between arms. Denoting the number of eligible participants
who consent by C, then,
E[N ] = E[N | C < nt]Pr(C < nt) + E[N | C ≥ nt]Pr(C ≥ nt).
Note that C follows a binomial distribution with size ne and probability φr.
Because recruitment will stop once the target has been reached, E[N | C ≥
nt] = nt. We also have
E[N | C < nt] =
∑nt−1
k=0 k
(
ne
k
)
φkr (1 − φr)
ne−k
Pr(C < nt)
,
and so
E[N ] =
nt−1∑
k=0
k
(
ne
k
)
φkr (1− φr)
ne−k + ntPr(C ≥ nt).
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Returning to equation 3, the second term is
E
[
V ar(E[Y¯1|F1, A] | F1)
]
= E
[
V ar
(
Aµ
F1
| F1
)]
= E
[
µ2
F 21
V ar(A | F1)
]
= E
[
µ2
F 21
F1φa(1− φa)
]
=
2µ2
φfE[N ]
φa(1 − φa).
Finally,
V ar(E[Y¯1|F1]) = V ar
(
E
[
Aµ
F1
| F1
])
= V ar
(
E [A | F1]
µ
F1
)
= V ar
(
F1φa
µ
F1
)
= 0.
This then gives
V ar(Y¯1) =
2σ2
φfE[N ]
+
2µ2
φfE[N ]
φa(1− φa).
The variance of the control group sample mean is
V ar(Y¯0) = E[V ar(Y¯0|F0)] + V ar(E[Y¯0|F0])
= E
[
σ2
F0
]
+ 0
=
2σ2
φfE[N ]
.
The power of the trial can then be obtained by substituting the expectation
and variance of the sample means into the usual formula (which, again, assumes
they are normally distributed):
g(φ) = Φ
(
E[Y¯1 − Y¯0]√
V ar(Y¯1 − Y¯0)
− z1−α
)
= Φ

 φaµ√
2σ2
φfE[N ]
+ 2µ
2
φfE[N ]
φa(1− φa) +
2σ2
φfE[N ]
− z1−α


= Φ
(
φaµ
√
φfE[N ]√
4σ2 + 2µ2φa(1 − φa)
− z1−α
)
= Φ(x(φ) − z1−α) ,
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